Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29694220 | 0.98 | KEAP1 (0.33) | KEAP1APEX1ALDH1A1GAAMAPT | |
| Hydrochloric Acid SCHEMBL26618459 | 0.98 | KEAP1 (0.33) | KEAP1APEX1ALDH1A1GAAMAPT | |
| SCHEMBL22355344 | 0.72 | NTRK1 (0.32) | APEX1 | |
| SCHEMBL9933113 | 0.71 | KEAP1 (0.41) | KEAP1APEX1HTR2C | |
| SCHEMBL21041640 | 0.70 | HTR2C (0.45) | HTR2C | |
| Hydrochloric Acid SCHEMBL18322001 | 0.70 | KEAP1 (0.40) | KEAP1APEX1HTR2C | |
| Hydrochloric Acid SCHEMBL26625864 | 0.70 | KEAP1 (0.40) | KEAP1APEX1HTR2C | |
| SCHEMBL22355519 | 0.68 | NTRK1 (0.35) | — | |
| SCHEMBL22355454 | 0.68 | NTRK1 (0.35) | — | |
| SCHEMBL22355459 | 0.68 | NTRK1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204526-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-06-30 | — | — | US | disclosed |
| WO-2020165776-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204526-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | KEAP1, NFE2L2, NQO1 | KEAP1 1/4885APEX1 2185/4885ALDH1A1 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.